The PBAC today recommended that Inflectra (infliximab), the first monoclonal antibody ‘mAb’ biosimilar registered in Australia, be added to the Pharmaceutical Benefits Scheme. The recommendation is the first step towards unlocking greater savings for Australia’s health system which currently spends more than $100 million annually on a comparable therapy, says Hospira. Inflectra will be used
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.